Yixin Yuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yixin Yuan has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Andreas R. Pfenning
Carnegie Mellon University
1 shared publication - David A. Bennett
Rush University Medical Center
1 shared publication - Easwaran Ramamurthy
Carnegie Mellon University
1 shared publication - Gwyneth Welch
Picower Institute for Learning and Memory, Massachusetts Institute of Technology
1 shared publication - Jemmie Cheng
Picower Institute for Learning and Memory, Massachusetts Institute of Technology
1 shared publication - Laura Gunsalus
Computational Biology Department, Carnegie Mellon University
1 shared publication
Latest Publications
- Open Access
Cell type-specific histone acetylation profiling of Alzheimer’s Disease subjects and integration with genetics
We profile genome-wide histone 3 lysine 27 acetylation (H3K27ac) of 3 major brain cell types from hippocampus and dorsolateral prefrontal cortex (dlPFC) of subjects with and without Alzheimer’s Disease (AD). We confirm that single nucleotide polymorphisms (SNPs) associated with late onset AD (LOAD) prefer to reside in the microglial histone acetylome, which varies most strongly with age. We observe acetylation differences associated with AD pathology at 3,598 peaks, predominantly in an oligodendrocyte-enriched population. Strikingly, these differences occur at the promoters of known early onset AD (EOAD) risk genes ( APP, PSEN1, PSEN2, BACE1 ), late onset AD (LOAD) risk genes ( BIN1, PICALM, CLU, ADAM10, ADAMTS4, SORL1 and FERMT2 ), and putative enhancers annotated to other genes associated with AD pathology ( MAPT ). More broadly, acetylation differences in the oligodendrocyte-enriched population occur near genes in pathways for central nervous system myelination and oxidative phosphorylation. In most cases, these promoter acetylation differences are associated with differences in transcription in oligodendrocytes. Overall, we reveal deregulation of known and novel pathways in AD and highlight genomic regions as therapeutic targets in oligodendrocytes of hippocampus and dlPFC.
Open AccessCell type-specific histone acetylation profiling of Alzheimer’s Disease subjects and integration with genetics
We profile genome-wide histone 3 lysine 27 acetylation (H3K27ac) of 3 major brain cell types from hippocampus and dorsolateral prefrontal cortex (dlPFC) of subjects with and without Alzheimer’s Disease (AD). We confirm that single nucleotide polymorphisms (SNPs) associated with late onset AD (LOAD) prefer to reside in the microglial histone acetylome, which varies most strongly with age. We observe acetylation differences associated with AD pathology at 3,598 peaks, predominantly in an oligodendrocyte-enriched population. Strikingly, these differences occur at the promoters of known early onset AD (EOAD) risk genes ( APP, PSEN1, PSEN2, BACE1 ), late onset AD (LOAD) risk genes ( BIN1, PICALM, CLU, ADAM10, ADAMTS4, SORL1 and FERMT2 ), and putative enhancers annotated to other genes associated with AD pathology ( MAPT ). More broadly, acetylation differences in the oligodendrocyte-enriched population occur near genes in pathways for central nervous system myelination and oxidative phosphorylation. In most cases, these promoter acetylation differences are associated with differences in transcription in oligodendrocytes. Overall, we reveal deregulation of known and novel pathways in AD and highlight genomic regions as therapeutic targets in oligodendrocytes of hippocampus and dlPFC.